Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

Polascik, Thomas J.

doi:10.1038/sj.pcan.4501019

Cited by 16 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some non-systematic reviews and specialists' opinions defend the idea that an appropriate bisphosphonate therapy can prevent this bone loss. [31][32][33][34] Clear identification of risk factors for osteoporosis in individual patients should aid treatment decisions about whether to use bisphosphonates and when to start them.…”

Section: Discussionmentioning

confidence: 99%

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

Neto

Tobias-Machado

Esteves

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to clarify the role of bisphosphonates in the treatment of osteoporosis in patients with prostate adenocarcinoma under androgen deprivation therapy (ADT). The Medline, EMBASE, Cancerlit and the American Society of Clinical Oncology abstract databases were searched for published randomized, placebo-controlled trials evaluating the usage of bisphosphonates in patients with prostate cancer (PC) under ADT. The outcomes assessed were fracture, osteoporosis, incidence of adverse events and changes in bone mineral density (BMD) during treatment. A total of 15 articles (2634 participants) were included in the meta-analysis. Treatment with bisphosphonates showed a substantial effect in preventing fractures (risk ratio (RR), 0.80; P ¼ 0.005) and osteoporosis (RR, 0.39; P o0.00001). Zoledronic acid showed the best number needed to treat (NTT), compared with placebo, in relation to fractures and osteoporosis (NNT ¼ 14.9 and NNT ¼ 2.68, respectively). The between-group difference (bisphosphonates vs placebo) in the lumbar spine and femoral neck BMD were 5.18 ± 3.38% and 2.35 ± 1.16%, respectively. This benefit of bone loss prevention could be reached without major side effects (cardiovascular or gastrointestinal events). Bisphosphonates are effective in preventing bone loss in patients with PC who are under ADT.

show abstract

Section: Discussionmentioning

confidence: 99%

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

Neto

Tobias-Machado

Esteves

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Risk factors related to ONJ have been characterized and include pre-existing dental pathology, the use of dental prostheses, or maxillofacial surgery. These should be avoided whenever bone-preserving therapy is administered, and patients should further benefit from regular dental checkups during therapy [33][34][35].…”

Section: Intravenous Bisphosphonatesmentioning

confidence: 99%

Androgen Deprivation and Bone

Lattouf

Fadlallah

Saad

2010

Curr Osteoporos Rep

View full text Add to dashboard Cite

Bone health in men with prostate cancer on androgen deprivation therapy (ADT) has gained increased attention in recent years. Therapies that are becoming available to prevent bone loss and associated complications are changing practice for this patient population. In addition to basic vitamin D and calcium supplementation, bisphosphonates may be an option to treat these patients, and denosumab, a receptor activator of nuclear factor-κB ligand inhibitor, has been proven to be effective in preventing bone loss through a randomized clinical trial. This review examines the importance of bone health in patients on ADT, with an overview of available treatment modalities and guidelines for managing these patients.

show abstract

“…In summary, androgen-deprivation therapy (ADT) in prostate cancer patients leads to a clinically significant bone loss that translates into a higher fracture risk at 5 years of 19.4%, compared with 12.6% in nonusers (p Ͻ .001) [50,51]. Placebo-controlled trials have shown that pamidronate (60 mg i.v.…”

Section: Emerging Evidence On the Future Role Of Bisphosphonates In Cmentioning

confidence: 99%

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

Wyngaert

Huizing²,

Fossion

et al. 2009

The Oncologist

View full text Add to dashboard Cite

The introduction of bisphosphonates in oncology has dramatically changed the management of patients with metastatic bone disease. In this manuscript, we thoroughly scrutinize the available body of clinical trials supporting the use of bisphosphonates in this setting and review new and ongoing research. Additionally, we summarize the data showing the benefits of bisphosphonate use in the prevention of treatment-induced bone loss and the intriguing emerging evidence on the antitumor potential of some of these agents when used in the adjuvant setting. Finally, we address the need for a careful consideration of potential benefits of bisphosphonate therapy and the risk for osteonecrosis of the jaw, a recently recognized late-toxicity of their use. The Oncologist 2009;14:181-191

show abstract

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

Cited by 16 publications

References 29 publications

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

Androgen Deprivation and Bone

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

Contact Info

Product

Resources

About